Try
VERACYTE, INC.
VCYTUnited States
96 filed reports · 509 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
96 reports · Dec 2014 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 130 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 49 | 136 | Mar 2015 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 35 | 5,021 | Mar 2015 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 12 | 5,060 | Dec 2014 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 31, 2026 | 386 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 30, 2026 | 4 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 268 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 5, 2026 | 4 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 1,042 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 25, 2026 | 4 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Jan 12, 2026 | 4 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 287 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 4, 2025 | 2 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 181 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 6, 2025 | 10 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 179 | Open |
Financial data
509 concepts · 10,217 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial476 concepts · 9,281 facts · Dec 2012 to Jul 2026
- Revenue68 · Dec 2012 to Jun 2026
- Cash and cash equivalents at carrying value66 · Dec 2012 to Jun 2026
- Comprehensive income net of tax64 · Dec 2012 to Jun 2026
- Depreciation depletion and amortization64 · Dec 2012 to Jun 2026
- General and administrative expense (US GAAP)64 · Dec 2012 to Jun 2026
- Increase decrease in accounts payable64 · Dec 2012 to Jun 2026
- Increase decrease in accounts receivable64 · Dec 2012 to Jun 2026
- Increase decrease in other noncurrent assets64 · Dec 2012 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets64 · Dec 2012 to Jun 2026
- Operating income loss64 · Dec 2012 to Jun 2026
- Other nonoperating income expense64 · Dec 2012 to Jun 2026
- Payments to acquire property plant and equipment64 · Dec 2012 to Jun 2026
- Proceeds from stock options exercised64 · Dec 2012 to Jun 2026
- Research and development expense64 · Dec 2012 to Jun 2026
- Selling and marketing expense (US GAAP)64 · Dec 2012 to Jun 2026
- Stockholders equity (US GAAP)63 · Dec 2012 to Jun 2026
- Increase decrease in inventories62 · Dec 2012 to Dec 2025
- Preferred stock par or stated value per share62 · Nov 2013 to Jun 2026
- Preferred stock shares authorized62 · Nov 2013 to Jun 2026
- Accounts payable current61 · Dec 2013 to Jun 2026
- Accounts receivable net current61 · Dec 2013 to Jun 2026
- Accrued liabilities current61 · Dec 2013 to Jun 2026
- Additional paid in capital common stock61 · Dec 2013 to Jun 2026
- Assets61 · Dec 2013 to Jun 2026
Product7 concepts · 436 facts · Dec 2017 to Jun 2026
- Revenue258 · Dec 2017 to Jun 2026
- Cost of revenue (US GAAP)120 · Dec 2018 to Jun 2026
- Accounts Receivable, Net27 · Dec 2020 to Jun 2026
- Operating expenses (US GAAP)17 · Dec 2022 to Jun 2026
- Contract with customer liability revenue recognized10 · Jun 2018 to Mar 2020
- Testing revenue3 · Dec 2017 to Dec 2019
- Inventory write down1 · Mar 2020
Segment16 concepts · 347 facts · Dec 2022 to Jun 2026
- Revenue56 · Dec 2022 to Jun 2026
- Cost of revenue (US GAAP)42 · Dec 2022 to Jun 2026
- Other cost of operating revenue42 · Dec 2022 to Jun 2026
- Testing revenue42 · Dec 2022 to Jun 2026
- Cost of goods and services sold amortization14 · Dec 2022 to Jun 2026
- Cost of goods and services sold (US GAAP)14 · Dec 2022 to Jun 2026
- General and administrative expense (US GAAP)14 · Dec 2022 to Jun 2026
- Gross profit (US GAAP)14 · Dec 2022 to Jun 2026
- Income tax expense benefit14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Operating expenses (US GAAP)14 · Dec 2022 to Jun 2026
- Other nonoperating income expense14 · Dec 2022 to Jun 2026
- Product revenue14 · Dec 2022 to Jun 2026
- Research and development expense14 · Dec 2022 to Jun 2026
- Selling and marketing expense (US GAAP)14 · Dec 2022 to Jun 2026
- Asset impairment charges11 · Dec 2022 to Jun 2026
Guidance8 concepts · 136 facts · May 2015 to Jul 2026
- Revenue Guidance98 · May 2015 to Jul 2026
- Revenue Growth Guidance22 · Nov 2021 to Jul 2026
- Free Cash Flow Guidance6 · Mar 2017 to Nov 2017
- EPS (Diluted) Guidance2 · Oct 2016
- Net Income Guidance2 · Oct 2016
- Revenue Growth Guidance (testing)2 · Aug 2025
- Revenue Growth Guidance (testing; Excluding divestitures)2 · Aug 2025
- Revenue Guidance (testing)2 · Aug 2025
Geography2 concepts · 17 facts · Dec 2018 to Dec 2025
- Revenue16 · Dec 2018 to Dec 2025
- Headquarters and laboratory facilities, South San Francisco, Lease signed in April 20151 · Mar 2020
Segments
800 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service21 members · 436 facts
- Product83 · Dec 2017 to Jun 2026
- Testing81 · Dec 2017 to Jun 2026
- Biopharmaceutical And Other62 · Dec 2019 to Jun 2026
- Biopharmaceutical27 · Dec 2017 to Jun 2021
- Biopharmaceutical And Other Biopharmaceutical Revenue27 · Dec 2020 to Jun 2026
- Biopharmaceutical and other27 · Dec 2020 to Jun 2026
- Biopharmaceutical And Other Contract Manufacturing And Testing26 · Dec 2020 to Jun 2026
- Testing Other19 · Dec 2021 to Jun 2026
- Intangible Asset Amortization17 · Dec 2022 to Jun 2026
- Biopharmaceutical And Other Contract Manufacturing9 · Dec 2019 to Mar 2022
- Biopharmaceutical And Other Contract Testing9 · Dec 2019 to Mar 2022
- Biopharmaceutical And Other Development Services9 · Dec 2019 to Mar 2022
- Biopharmaceutical And Other Provision Of Data9 · Dec 2019 to Mar 2022
- Biopharmaceutical And Other Development Rights7 · Dec 2019 to Dec 2021
- Biopharmaceutical And Other Collaboration Milestones5 · Dec 2019 to Dec 2023
- Biopharmaceutical And Other Milestones4 · Sep 2020 to Mar 2022
- Collaboration4 · Dec 2017 to Dec 2020
- Service4 · Sep 2018 to Sep 2019
- Biopharmaceutical And Other Milestones Excluding Collaboration3 · Dec 2019 to Dec 2021
- Collaborative3 · Sep 2019 to Sep 2020
- Diagnostic Services1 · Mar 2019
Statement business segments1 member · 347 facts
- Reportable347 · Dec 2022 to Jun 2026
Statement geographical3 members · 17 facts
- Non Us8 · Dec 2018 to Dec 2025
- US8 · Dec 2018 to Dec 2025
- Headquarters And Laboratory Facilities South San Francisco Lease Two1 · Mar 2020
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.